Recent advancements in the application of circulating tumor DNA as biomarkers for early detection of cancers
M Mishra, R Ahmed, DK Das… - ACS Biomaterials …, 2024 - ACS Publications
Early detection of cancer is vital for increasing patient survivability chances. The three major
techniques used to diagnose cancers are instrumental examination, tissue biopsy, and …
techniques used to diagnose cancers are instrumental examination, tissue biopsy, and …
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research
EM Lauer, J Mutter, F Scherer - Leukemia, 2022 - nature.com
Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …
profiling has become a potential novel strategy for patient management in B-cell lymphoma …
[HTML][HTML] Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
Genomic profiling for clinical decision making in lymphoid neoplasms
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …
Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas
PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably
heterogeneous, yet identification of patients at high risk for treatment failure is challenging …
heterogeneous, yet identification of patients at high risk for treatment failure is challenging …
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma
RC Lynch, CS Ujjani, C Poh, EH Warren… - Blood, The Journal …, 2023 - ashpublications.org
Concurrent administration of pembrolizumab with chemotherapy in untreated classic
Hodgkin lymphoma (CHL) has not been studied previously. To investigate this combination …
Hodgkin lymphoma (CHL) has not been studied previously. To investigate this combination …
Sequencing therapy in relapsed DLBCL
CR Flowers, OO Odejide - Hematology, 2022 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy
worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of …
worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of …
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA
JM Heger, J Mattlener, J Schneider, P Gödel, N Sieg… - Blood, 2024 - ashpublications.org
State-of-the-art response assessment of central nervous system lymphoma (CNSL) by
magnetic resonance imaging is challenging and an insufficient predictor of treatment …
magnetic resonance imaging is challenging and an insufficient predictor of treatment …